Precision Lipid Management after Stroke: Promise Meets Practice

Patients with ischemic stroke face a substantial risk of recurrent cerebrovascular events, with population-based cohort studies estimating a 5-year recurrence risk of 10% to 15%.[1] Efforts to reduce residual atherosclerotic and thrombotic risk require a multidisciplinary effort and aim to target multiple modifiable risk factors, such as lipids. The field of lipid management has transformed over the past few decades with the development of novel agents and molecular targets, allowing for a greater diversity in treatment modalities for the purpose of cerebrovascular disease prevention ([Fig. 1]). In a recent paper in this journal, Kolios et al provide a comprehensive review and examination of the evolving literature and advances in the field of lipid management after ischemic stroke.[2] In addition, a consensus paper of the International Lipid Expert Panel (ILEP) in collaboration with the European Society of Cardiology (ESC) Council on Stroke provides a state-of-the-art overview on lipid management for primary and secondary stroke prevention.[3]

Publication History

Received: 03 December 2025

Accepted: 04 December 2025

Accepted Manuscript online:
14 January 2026

Article published online:
21 January 2026

• References

• 1 Flach C, Muruet W, Wolfe CDA, Bhalla A, Douiri A. Risk and secondary prevention of stroke recurrence: A population-base cohort study. Stroke 2020; 51 (08) 2435-2444
• 2 Kolios NG, Barkas F, Ntaios G, Milionis H. Strategic lowering of LDL-cholesterol post ischemic stroke: Identifying optimal targets, timing, and therapeutic approaches. Thromb Haemost 2025; (e-pub ahead of print).
• 3 Banach M, Toth PP, Ahn HJ. et al; International Lipid Expert Panel and in collaboration with the European Society of Cardiology Council on Stroke. Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis 2025; S0 033–0620(25)00166–5
• 4 Heo JH, Song D, Nam HS. et al; EUREKA Investigators. Effect and safety of rosuvastatin in acute ischemic stroke. J Stroke 2016; 18 (01) 87-95
• 5 Montaner J, Bustamante A, García-Matas S. et al; STARS Investigators. Combination of thrombolysis and statins in acute stroke is safe: Results of the STARS Randomized Trial (Stroke Treatment with Acute Reperfusion and Simvastatin). Stroke 2016; 47 (11) 2870-2873
• 6 Blanco M, Nombela F, Castellanos M. et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69 (09) 904-910
• 7 Choi SE, Bucci T, Huang JY. et al. Early statin use is associated with improved survival and cardiovascular outcomes in patients with atrial fibrillation and recent ischaemic stroke: A propensity-matched analysis of a global federated health database. Eur Stroke J 2025; 10 (01) 116-127
• 8 Lip GYH, Ntaios G. “Novel clinical concepts in thrombosis”: Integrated care for stroke management-easy as ABC. Thromb Haemost 2022; 122 (03) 316-319
• 9 Buckley BJR, Harrison SL, Hill A, Underhill P, Lane DA, Lip GYH. Stroke-heart syndrome: Incidence and clinical outcomes of cardiac complications following stroke. Stroke 2022; 53 (05) 1759-1763
• 10 Lip GYH, Lane DA, Lenarczyk R. et al. Integrated care for optimizing the management of stroke and associated heart disease: A position paper of the European Society of Cardiology Council on Stroke. Eur Heart J 2022; 43 (26) 2442-2460
• 11 Tsang CTW, Choi SE, Bucci T. et al. Integrated care using the ABC_stroke pathway improves cardiovascular outcomes and survival in patients with first-ever ischaemic stroke. Glob Heart 2025; 20 (01) 46
• 12 Sagris D, Lip GΥΗ, Korompoki E, Ntaios G, Vemmos K. Adherence to an integrated care pathway for stroke is associated with lower risk of major cardiovascular events: A report from the Athens Stroke Registry. Eur J Intern Med 2024; 122: 61-67
• 13 Ortega-Paz L, Franchi F, Angiolillo DJ. The lipid-platelet interplay: Unraveling the effects of PCSK9 inhibition on platelet reactivity. Thromb Haemost 2024; 124 (06) 528-532
• 14 Kleindorfer DO, Towfighi A, Chaturvedi S. et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A guideline from the American Heart Association/American Stroke Association. Stroke 2021; 52 (07) e364-e467
• 15 Amarenco P, Kim JS, Labreuche J. et al; Treat Stroke to Target Investigators. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 2020; 382 (01) 9-19
• 16 Mach F, Baigent C, Catapano AL. et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41 (01) 111-188
• 17 Sabatine MS, Giugliano RP, Keech AC. et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376 (18) 1713-1722
• 18 Schwartz GG, Steg PG, Szarek M. et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379 (22) 2097-2107
• 19 Pfeferman MB, Rashedi S, Lip GYH. et al. Lipoprotein(a) and venous thromboembolism: Association, causality, and medications. Thromb Haemost 2025; 125 (11) 1069-1084
• 20 Koh MY, Toh KZ, Loh ED. et al. Association of elevated lipoprotein(a) levels with ischemic stroke in young patients - a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2024; 33 (11) 107960
• 21 De Los Reyes C, Rikhi RR, Doherty S. et al. Current clinical trials for treating elevated lipoprotein(a). Curr Cardiovasc Risk Rep 2025; 19 (01) 7
• 22 Kronenberg F, Mora S, Stroes ESG. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43 (39) 3925-3946
• 23 Schumann F, Kassner U, Spira D. et al. Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevation. J Clin Lipidol 2024; 18 (05) e738-e745
• 24 Gianos E, Duell PB, Toth PP. et al; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Lifelong Congenital Heart Disease and Heart Health in the Young; and Council on Peripheral Vascular Disease. Lipoprotein apheresis: Utility, outcomes, and implementation in clinical practice: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2024; 44 (12) e304-e321